



A Better Path to Well

INVESTOR PRESENTATION | CONFIDENTIAL | February 2026

Disclaimer

Cautionary Note – Scope of Presentation, Confidentiality, and Risk of Loss

This presentation (the "Presentation") of Vector Science & Therapeutics Inc. (the "Company" or "our" or "we") is current as of February 2026 and the information set out herein is current as of such date except as otherwise indicated. It is information in a summary form and does not purport to be complete. The information herein is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor.

In addition, this Presentation is confidential and for the intended recipient's use only. The contents are not to be communicated, reproduced or distributed to the public or the press. This Presentation should be read in conjunction with and is qualified in its entirety by reference to any subscription agreement of any offering of securities, as such securities may be related to the Company. All of the information contained in this Presentation is for preliminary discussion purposes only. Final terms and conditions may change without notice and are subject to further discussion and negotiations.

An investment in the Company is speculative, involves substantial risks, and is limited to accredited investors that are able to bear the risk of losing their entire investment. See "Risk Factors".

Cautionary Note – Forward Looking Statements

Certain statements in this Presentation may constitute "forward-looking information" within the meaning of applicable securities laws. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "expects," "believes," "anticipates," "budget," "scheduled," "estimates," "forecasts," "intends," "plans," and variations of such words and phrases, or by statements that certain actions, events or results "may," "will," "could," "would," or "might," "be taken," "occur," or "be achieved."

Forward-looking information contained in this Presentation are based on certain assumptions regarding, among other things, expectations regarding: demand for the Company's products; timing for regulatory approvals, anticipated effectiveness of our products, anticipated cash needs; ability to anticipate the future needs of customers; plans for future products and enhancements of existing products; future growth strategy and growth rate; future intellectual property, research and development, product formulations and business lines; and anticipated trends related to the global pharmaceutical industry.

Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements. Any forward-looking statements are made as of the date of this Presentation. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Cautionary Note – Forward Looking Statements (Continued)

No representation or warranty, express or implied, is made or given by or on behalf of the Company or any of its affiliates, directors, officers or employees as to the accuracy, completeness or fairness of the information or opinions contained in this Presentation and no responsibility or liability is accepted by any person for such information or opinions. The Company does not undertake or agree to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation that may become apparent. Persons receiving or reviewing this Presentation should not rely upon it as a complete overview of the business of the Company and should rely on their own investigation and due diligence.

Certain information contained herein is based on, or derived from, information provided by independent third-party sources. The Company believes that such information is accurate and that the sources from which it has been obtained are reliable. The Company cannot guarantee the accuracy of such information, however, and has not independently verified the assumptions on which such information is based. The Company does not assume any responsibility for the accuracy or completeness of such information.

This Presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of securities of the Company in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

NOTE TO U.S. PERSONS: The securities referenced in this Presentation have not been approved or disapproved by the United States Securities and Exchange Commission or by any state securities commission or regulatory authority. The securities of the Company have not been and will not be registered under the United States Securities Act of 1933, as amended, or the securities laws of any state. No securities exchange accepts responsibility for the adequacy or accuracy of this Presentation.

Vector Science & Therapeutics develops novel biomechanical devices and active transdermal drug delivery platforms to equip clinicians with non-systemic, localized interventions targeting a broad cross-section of diseases and conditions where systemic delivery of interventions compromises the therapeutic effect or introduces unacceptable harm.

Why We Do It

We are committed to improving the lives of patients and the practice of medicine by developing and commercializing technologies that improve clinical outcomes, reduce the economic burden of treatment for patients and payers, and leverage insight secured across the patient's journey with our products to equip medical professionals to deliver personalized intervention.

How We Do It

Our product platforms equip clinicians to deliver interventions into targeted anatomical regions and tissue ('Smart, Steered, and Sustained') to optimize the efficacy potential of biomechanical devices, pharmaceuticals and biologics.

Why We Are Equipped to Do It

The Vector Science & Therapeutics team brings extensive experience in developing and commercializing advanced drug delivery platforms, with deep expertise in transdermal delivery modalities including iontophoresis and sonophoresis. Leveraging our experience, our curiosity, and our strategic partnerships, we ensure access to non-systemic interventions manufactured under the highest cGMP standards.

Tommy Thompson

Lead Independent Director

- Former US Secretary of Health & Human Services (2001-2005)
- 42nd Governor of Wisconsin (1987-2001), longest-serving in state history
- Led Medicare prescription drug benefit passage and implementation
- Chairman, Global Fund to Fight AIDS, Tuberculosis & Malaria (2003-2005)

Bill Jackson

Chief Executive Officer

- 25+ years medical device industry as entrepreneur and C-suite executive
- Co-founder, Attwill Medical Solutions (cGMP lyophilization partner)
- Co-founder, Preferred Medical Products (sold to Ballard Medical/Tyco)
- Former CFO/COO, Covalon Technologies (TSX-V listed)
- Industry foundation: Karl Storz and Stryker (top-10 worldwide roles)

W. Bradley Worthington, MD, FASA, DABA

Chief Medical Officer

- Triple Board-certified: Anesthesiology, Critical Care Medicine, and Pain Medicine
- 40+ years transformative leadership in anesthesiology and pain management
- Practicing physician with clinical foundation from UPENN, CHOP, and Vanderbilt University
- Experienced anesthesiologist focused on multi-modal approaches to non-narcotic pain management

Barry Hix, MBA, MPH

Chief Commercial Officer

- 25+ years commercial strategy leadership across pharmaceutical, healthcare delivery, medical device, and MedTech: Merck, HealthSouth, Enovis/DonJoy/Empi
- Built and scaled organizations and brands across orthopedic, regenerative medicine, and pain management markets for Fortune 50 and private-equity (Carlisle/Blackstone).
- Pioneered mHealth enterprise platforms adopted by Walgreens, AmerisourceBergen, McKesson
- Active at intersection of AI and life sciences, delivering smarter brand-patient connections

Stephen Gledhill, CPA

Chief Financial Officer

- 30+ years C-suite and senior executive leadership across corporate and entrepreneurial sectors
- Trusted advisor and strategic partner to startups and growth-stage companies navigating complex financial and operational challenges
- Proven track record building and scaling organizations in pharmaceuticals, nutraceuticals, manufacturing, commercial real estate, and mining/minerals exploration
- Deep experience across government, pension plan administration, and private-sector finance, bringing institutional discipline to entrepreneurial

Tom Bachinski, MSME, MBA

Chief Technology Officer

- Decades of specialized expertise in medical device and drug delivery
- Product design and engineering across diverse medical device categories
- 510(k) submission and design controls leadership
- Leading platform development across VectorMist and biomechanical modules
- Cross-industry insights from drug delivery to wellness technologies
- Holds over 100 patents across medical device, drug delivery, and other industries

Tabitha Hendren, MS

Director, Engineering and Design

- MS & BS Biomedical Engineering, University of Michigan
- 4+ years medical device development and clinical research
- Former Biomedical Engineer at ZetrOZ Systems (sonophoresis drug delivery)
- Manufacturing operations and product development expertise
- Leading product development for transdermal drug delivery platforms

We must acknowledge the human burden created by systemic approaches (including drugs) to intervention. A burden that will continue to grow as our population ages...unless we begin to create new pathways to intervention.

107,000+

**Drug Overdose Deaths Annually
(U.S.)**

Opioid prescriptions for pain management fuel a dependency crisis. What begins as legitimate medical treatment becomes addiction, overdose, and death. Families destroyed. Communities devastated. A national tragedy born from systemic exposure to narcotics.

CDC / National Center for Health Statistics (NCHS),
National Vital Statistics System

65+

**Average Age with 5+ Chronic
Conditions**

Degenerative disease robs millions of mobility, independence, and quality of life. Arthritis. Neuropathy. Chronic pain. Each condition treated with another pill. Compounding the side effects. Limiting function. Stealing years from people who deserve better.

Trends in Multiple Chronic Conditions Among US
Adults, By Life Stage, Behavioral Risk Factor
Surveillance System, 2013–2023

50%

Of Seniors Take 5+ Medications Daily

Polypharmacy creates a cascade of drug-to-drug and drug-to-disease interactions. The liver and kidneys struggle. Cognitive decline accelerates. Falls increase. Hospital admissions multiply. The very treatments meant to help become catalysts for harm.

Study: Polypharmacy Nearly Doubled in 20 Years
Among Older Adults in US | Clinical Pharmacy and
Pharmacology | JAMA | JAMA Network

THE PROBLEM WITH SYSTEMIC DELIVERY



Wrong Target

Older adults and obese individuals experience poor drug targeting primarily through altered body composition that misdirects drugs away from therapeutic targets and into non-target tissues.

[Age-related changes in pharmacokinetics - PubMed](#)



Higher Doses & Toxicity

Systemic delivery demands higher doses to achieve therapeutic effect at the target site, multiplying side effects, drug interactions, and organ stress.

[Pharmacokinetics of obese adults: Not only an increase in weight - PubMed](#)



Compliance Failure

Multi-dose regimens create burden. Patients miss doses. Outcomes suffer. Repeat prescribing drives up cost and opens doors to dependence.

[Association between medication regimen complexity and pharmacotherapy adherence: a systematic review - PubMed](#)

Our Approach

FOUNDATIONAL PILLARS

Three principles define how Vector delivers therapeutic advantage across every product in our portfolio

SMART

Adaptive. Data-driven. Patient-responsive.

Smart delivery means the platform optimizes the therapeutic effect in response to measurable physiological signals rather than relying on population-average dosing schedules.

MECHANISM

Biomarker-responsive dosing

CLINICAL BENEFIT

Optimized therapeutic index per patient

ADVANTAGE

Eliminates fixed-protocol underdosing and overdosing risk

EXPRESSED IN · VectorMist · Biomechanical Module · Transdermal Platform

STEERED

Site-directed. Non-systemic. On target.

Steered delivery is not simply local administration; it is mechanically guided delivery to a precise anatomical target, enabling therapeutic concentrations at the site while eliminating systemic drug burden.

MECHANISM

Mechanically guided non-systemic delivery

CLINICAL BENEFIT

Full therapeutic concentration at target; zero systemic burden

ADVANTAGE

Directly supports 510(k) non-systemic classification

EXPRESSED IN · VectorMist · Biomechanical Module · Transdermal Platform

SUSTAINED

Continuous effect. No compliance required.

Sustained delivery keeps the therapeutic in the targeted anatomical region to help ensure the desired clinical effect while also addressing the single greatest failure point in outpatient therapeutics: the gap between prescribed and consumed.

MECHANISM

Extended-duration site-directed release

CLINICAL BENEFIT

Therapeutic window maintained without patient action

ADVANTAGE

Eliminates compliance gap — the #1 failure point in outpatient therapy


EXPRESSED IN · VectorMist · Biomechanical Module · Transdermal Platform

TRANSLATED ADVANTAGE

ATTRIBUTE	VECTOR PLATFORMS	Conventional Drug Delivery	Systemic Injection	Current DME
Non-systemic delivery	✓ Yes	✗ No	✗ No	✗ No
No injection required	✓ Yes	✗ No	✗ No	✓ Yes
Targeted tissue delivery	✓ Yes	⦿ Partial	✗ No	⦿ Partial
Sustained effect	✓ Yes	⦿ Partial	✗ No	⦿ Partial
Opioid-free pathway	✓ Yes	⦿ Partial	✗ No	✓ Yes
Smart dosing / biomarkers	✓ Yes	✗ No	✗ No	✗ No
Multi-therapeutic platform	✓ Yes	✗ No	✗ No	✗ No

Vector platforms deliver Smart, Steered, and Sustained therapy across drug delivery, durable medical equipment (DME) and peptide markets.

DEVELOPMENT ROADMAP



Quarterly references are to Vector's fiscal periods. Vectors' year end is August 31 and for certainty, references to "2027" refer to the fiscal year ending August 31, 2027 and so forth for other fiscal year references.

VectorMist is a laparoscopic delivery device that atomizes therapeutic agents directly onto the peritoneal surface during surgery. Unlike instillation methods that allow fluid to pool in dependent areas, VectorMist's atomization technology creates fine droplets that achieve 360° peritoneal coverage, enabling precise targeting of key anatomic structures.

How VectorMist Works

- 1 Catheter-based Laparoscopic Atomizing Solution System inserted into laparoscopic port
- 2 Atomizes a surgeon/anesthesiologist-defined therapeutic combination per the LASSO protocol
- 3 Delivers mist directly into the operative field for hernia repair, cholecystectomy, and other procedures
- 4 Tissue infiltration without systemic exposure, delivering an analgesic effect that is faster and lasts longer (extending the pain mitigation window into the postoperative recovery phase)
- 5 Patients recover faster and exit the recovery unit sooner

Market Opportunity

4.8M laparoscopic surgeries/year (U.S.)

[Laparoscopy Devices Market Size, Share, Trend | CAGR of 11.9%](#)

Non-Opioid Path

Supports surgeons seeking opioid-free pain management

Faster Recovery

Reduced Post Anesthesia Care Unit (PACU) time and same-day discharge potential

510(k) Pathway

Class II predicate strategy; submission in process

Laparoscopic Surgery: Market Share & Growth by Facility Type

Current distribution, projected annual growth, and strategic relevance for VectorMist

FACILITY TYPE	DESCRIPTION & COMMON PROCEDURES	SHARE	ANNUAL GROWTH	STRATEGIC NOTE
Ambulatory Surgery Centers ASCS	Fastest-growing setting. CMS expanding approved procedure list; payers actively pushing volume here due to cost advantages. Cholecystectomy Hernia repair Appendectomy Gynecologic	72%	▲ +2.5% / yr	Primary VectorMist target. Highest-volume, most autonomous surgeons. Physician-owned model reduces VAC friction. Caresyntax can identify high-volume ASC sites for prioritized outreach.
Hospital Outpatient Dept. HOPD	Large, established segment. Same-day surgery now standard for lower-complexity cases, though losing share to ASCs on cost grounds. Cholecystectomy Appendectomy Hernia repair Gynecologic	18%	▲ +1.8% / yr	Secondary target. Higher institutional complexity with VAC involvement likely. Strong for outcomes data collection and thought leadership given academic HOPD affiliation.
Hospital Inpatient (OR) INPATIENT	Declining share as cases migrate outward. Remains home to highest-complexity and highest-acuity laparoscopic cases. Colectomy Bariatric Oncologic resection Major gynecologic	10%	▼ -1.0% / yr	Lower priority for early adoption. Complex cases involve longer operative times and conversion risk. Potential for expanded indication as VectorMist clinical data matures.

Sources: ASCA, Sg2, Grand View Research, Market Growth Reports, CMS (2023–2024)



Targeted Intervention.
Intelligently Delivered.

In addition to representing the largest share of laparoscopic procedures, ASCs are characterized by autonomous clinician decision making, reducing or eliminating the need to accommodate the Value Analysis Committee approval process. By leveraging data from surgical intelligence platforms, capabilities to identify and rank high-volume laparoscopic ASCs geographically, Vector can deploy a precision targeting strategy that focuses commercial resources on the facilities and surgeons most likely to drive early adoption, generate outcomes data, and serve as reference sites for broader market expansion.



THE LASSO PROTOCOL

LASSO DEFINED

- L** Laparoscopic
- A** Atomization
- S** Solution for
- S** Sparing
- O** Opiates

Establishing the LASSO Protocol as the clinical standard requires deliberate engagement of the surgeons and institutions who shape peer behavior, generate publishable evidence, and set the expectations of early adopters in laparoscopic surgery.

High-Volume Laparoscopic Surgeons

CLINICAL CHAMPIONS

General and minimally invasive surgeons performing 20 or more laparoscopic cases per month are the primary target. These practitioners have the procedure volume to generate outcomes data rapidly, the peer credibility to influence adoption within their practice group, and the clinical authority to champion protocol changes in their ASC or hospital system. Early adopters become the reference surgeons who anchor VectorMist's published case series and registry data.

Anesthesiology Partners

PERIOPERATIVE INTEGRATORS

Anesthesiologists control perioperative pain management protocols and are natural allies in opioid-sparing initiatives. Their endorsement of the LASSO Protocol as a multimodal analgesia component is intended to validate the pharmacologic rationale for atomized delivery and creates a cross-disciplinary adoption pathway. ERAS protocol committees within health systems represent a structured entry point for institutional integration.

Surgical Society KOLs

PROTOCOL VALIDATORS

Key opinion leaders affiliated with SAGES, ACS, and specialty societies carry disproportionate influence over protocol adoption across the surgical community. Engaging two to four KOLs to present LASSO Protocol outcomes at major annual meetings creates a peer-validation halo that accelerates adoption beyond what direct sales can achieve. Podium presentations and peer-reviewed publications authored by recognized names establish scientific legitimacy.

ASC Medical Directors

INSTITUTIONAL GATEKEEPERS

Medical directors at high-volume laparoscopic ASCs function as both clinical leaders and operational decision-makers. Their adoption of the LASSO Protocol as a facility standard drives systematic, repeatable use across every surgeon on staff, multiplying impact beyond a single champion relationship. Clinical data identifying top-volume laparoscopic ASCs enables precision targeting of these influencers at the facility level.

The LASSO Protocol

CLINICAL AND ECONOMIC OUTCOMES

The intention of the multimodal, non-systemic approach is to support measurable clinical improvements aligned with facility efficiency goals and the surgical community's growing emphasis on reducing opioid dependence across the perioperative continuum. The clinical outcomes presented here represent targeted objectives. Post-market validation of real-world results will be administered by an independent third party to confirm that real-world evidence (RWE) aligns with intended performance targets.

Ref: Non-opioid multimodal analgesia protocols including local anesthetic adjuvants demonstrate significant reductions in postoperative opioid consumption, total morphine equivalents, and PACU recovery time across ambulatory and hospital-based laparoscopic surgical patients. (Beverly et al., Pain Physician, 2017; Lavand'homme & Steyaert, Curr Opin Anaesthesiol, 2017; Kehlet & Dahl, Lancet, 2003)

up to 40%

VECTOR MIST INTENDED
REDUCTION IN POSTOPERATIVE
OPIOID USE

VectorMist delivers bupivacaine and LASSO adjuvants directly to the surgical site, aimed at reducing the systemic opioid burden from the moment of closure. Non-systemic delivery is intended to eliminate CNS side effects of IV opioids while maintaining superior site-level pain control, supporting opioid-sparing surgical protocols increasingly mandated by payers and health systems across all facility types.

up to 30%

VECTOR MIST INTENDED
REDUCTION IN MORPHINE
EQUIVALENT DOSES (MEDS)

Lower MED requirements can translate directly into reduced risk of opioid-related adverse events including respiratory depression, nausea, constipation, and prolonged sedation. For ASC-based surgeons, MED reduction supports same-day discharge criteria and reduces the risk of post-discharge opioid complications that generate downstream liability and readmission risk.

20–40 min

VECTOR MIST INTENDED
REDUCTION IN POST-OPERATIVE
RECOVERY TIME ACROSS ALL
FACILITY TYPES

Effective perioperative pain control is the primary driver of PACU time in laparoscopic cases. By attenuating pain at its source, the LASSO Protocol intends to accelerate recovery milestones and enables earlier discharge readiness in ASCs, HOPDs, and inpatient settings. For high-volume ASCs, faster PACU clearance directly improves OR throughput, case volume capacity, and per-room profitability.

Projected Market Penetration



			Fiscal ²	
Potential market ¹	4.8M U.S. units annually	2027	2028	2029
Projected market penetration		0.26%	0.55%	0.88%
Projected market penetration growth		-	111.7%	60.7%
Estimated ³ units captured =		12,480	28,000	47,680
Estimated procedures per surgeon (annually) x		80	80	80
Estimated number of surgeons/facility x		2	2	2
Estimated number of facilities		78	175	298

¹Laparoscopy Devices Market Size, Share, Trend | CAGR of 11.9%

²Fiscal year ended August 31st.

³Estimates have been made by management based on medical and market experience and may not reflect actual results.

ONE PLATFORM. THREE DISTINCTIVE PRODUCTS.



Our proprietary biomechanical platform delivers therapeutic effects as a standalone technology, as a synergistic complement to therapeutic peptides, and as a partner to pharmaceuticals.

LEVERAGING THREE FOUNDATIONAL PILLARS

SMART

Leverages device utilization data and biomarkers to deliver optimized dosing

01

Biomechanical Delivery

Therapeutic effect on musculoskeletal targets using electrical and magnetic fields, standalone or synergistic

\$58B

GLOBAL MUSCULOSKELETAL MARKET

STEERED

Directed therapeutic delivery to targeted tissues and treatment sites

02

Active Transdermal Peptide/Drug Delivery

Targeted peptide delivery into anatomical regions for optimized therapeutic effect and bioavailability

\$50B

GLOBAL DRUG / PEPTIDE THERAPEUTICS

SUSTAINED

Continuous therapeutic effect over extended treatment periods

03

Active Transdermal Drug Delivery

Site-directed delivery of therapeutic agents into targeted anatomical regions for optimized clinical effect

\$45B

GLOBAL POST-OP PAIN MANAGEMENT

Market sources aligned with TAM/SAM/SOM analysis: Musculoskeletal (Market Data Forecast, 2024); Peptide Therapeutics (IMARC / Global Market Insights, 2025 · 7–11% CAGR); Post-op Pain Management (Mordor Intelligence, 2026). All figures represent global TAM consistent with accompanying market opportunity slide.

MARKET OPPORTUNITY

NON-SYSTEMIC INTERVENTION DELIVERY ACROSS FOUR THERAPEUTIC MARKETS

AGGREGATE SOM ACROSS ALL FOUR PLATFORMS // ~\$3.35B // 5-Year U.S. Target

Vector platforms target ~15–25% of each total market: the fraction addressable via site-directed, non-systemic delivery — bypassing systemic drug burden, reducing adverse events, and enabling ASC-compatible same-day protocols.

	PERIOPERATIVE PAIN MANAGEMENT	MUSCULOSKELETAL Ortho · Sports · Occupational	REGENERATIVE MEDICINE	DRUG / PEPTIDE THERAPEUTICS
TAM Total Addressable Market	\$45B Global post-op pain management (Mordor Intelligence, 2026)	\$58B Global musculoskeletal market (Market Data Forecast, 2024)	\$38B Global regenerative medicine (Grand View Research, 2025 · 17–19% CAGR)	\$50B Global peptide therapeutics (IMARC / Global Market Insights, 2025 · 7–11% CAGR)
SAM Non-Systemic Intervention Component	▼ NON-SYSTEMIC FILTER \$9B ~20% of TAM	▼ NON-SYSTEMIC FILTER \$11B ~19% of TAM	▼ NON-SYSTEMIC FILTER \$13B ~34% of TAM	▼ NON-SYSTEMIC FILTER \$8B ~16% of TAM
SOM Vector Platform Capture (5-yr U.S.)	▼ VECTOR PLATFORM FOCUS \$850M U.S. laparoscopic ASC atomized LASSO Protocol, 5-yr	▼ VECTOR PLATFORM FOCUS \$900M U.S. orthopedic + sports medicine ASC — biomechanical module	▼ VECTOR PLATFORM FOCUS \$1.1B U.S. surgical site regenerative delivery — biomechanical + VectorMist	▼ VECTOR PLATFORM FOCUS \$500M U.S. surgical site + transdermal peptide delivery, Q4 2027
	NON-SYSTEMIC QUALIFIER Local/regional anesthesia, atomized & infiltrated delivery, excludes systemic opioids, IV analgesics, oral NSAIDs	NON-SYSTEMIC QUALIFIER Injectable biologics, PRP, growth factor delivery at surgical site, excludes systemic DMARDs, oral NSAIDs, implants	NON-SYSTEMIC QUALIFIER Locally deliverable cell-based & biologic therapies, excludes systemic gene therapy, IV infusion CAR-T, systemic biologics	NON-SYSTEMIC QUALIFIER Transdermal, topical, and site-directed peptide delivery, excludes systemic SC/IV peptide injections (GLP-1, insulin, oncology)

Market sources: Post-op pain (Mordor Intelligence, 2026); Musculoskeletal (Market Data Forecast, 2024); Regenerative Medicine (Grand View Research / Mordor Intelligence, 2025); Peptide Therapeutics (Global Market Insights / IMARC, 2025). SAM = non-systemic, site-directed delivery component. SOM = U.S.-focused 5-year capture estimate based on VectorMist/LASSO Protocol commercial trajectory and Vector platform pipeline.

Patents Filed (2)

Multimodal neuromodulatory pain management and active vectored transdermal pharmaceutical platform delivery system.

Interoperative drug delivery catheter for spraying fluid-based medicine into endoscopic body cavities.

Additional patents to be filed in 2026.

Why Vector?

- ✓ Platform strategy: one infrastructure, multiple potential revenue streams
- ✓ Intended to be first-to-market in atomizing intraoperative delivery (3Q 2026)
- ✓ Non-opioid, non-systemic: aligned with CMS and payer priorities
- ✓ Strong IP moat around biomechanical + drug + peptide combination
- ✓ Validated commercial leadership with tier-1 healthcare experience
- ✓ Multiple partnership frameworks already advancing
- ✓ Leadership team has deep experience in product development, commercialization, and scaling brands and organizations in medical technology and specifically in the targeted disease and condition states

Risk Factors

Risk Factors

The Company has a limited operating history, is early in its development efforts, and has no products approved for commercial sale, which may make it difficult for you to evaluate the Company's current business and predict its future success and viability.

The Company is a therapeutics company with a limited operating history upon which you can evaluate our business and prospects. The Company has no products approved for commercial sale and has not generated any revenue from product sales. The production of therapeutics medical devices is a highly uncertain undertaking and involves a substantial degree of risk. To date, we have devoted substantially all of our resources and efforts to developing our products, building our intellectual property portfolio, business planning, and providing general and administrative support for these operations. The Company has not yet demonstrated an ability to successfully initiate or complete any pivotal clinical trials, obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on its behalf, or conduct sales and marketing activities necessary for successful product commercialization. As a result, it may be more difficult for you to accurately predict the Company's future success or viability.

In addition, the Company may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently experienced by early-stage therapeutics companies in rapidly evolving fields. If the Company does not adequately address these risks and difficulties or successfully make such a transition, its business will suffer.

The Company has incurred losses since inception and expects to incur losses for the foreseeable future and may never achieve or maintain profitability.

The Company has a history of losses and may never achieve or maintain profitability. The Company expects that its expenses will substantially increase if and as the Company continues to develop its products. To become and remain profitable, the Company must either develop and eventually commercialize a product or products with significant market potential on their own, or in collaboration with a partner. These development and commercialization activities are challenging. The Company may never realize revenue from its products and even if it does, it may not generate sufficient revenue to be profitable. Profitability may not be sustainable or be able to be increased once achieved.

Risk Factors Continued

The Company expects to require additional capital to support its business, and this capital might not be available on acceptable terms, if at all.

The Company intends to continue to make investments to support its business and will likely require additional funds. In particular, the Company expects to seek additional funds to develop new products and cover the cost of the clinical trials in respect of those products, enhance its platform and expand its operations, including its sales and marketing operations. Accordingly, the Company expects to engage in equity and/or debt financings to secure additional funds. If the Company raises additional funds through future issuances of equity or convertible debt securities, you could suffer significant dilution, and any new equity securities the Company issues could have rights, preferences and privileges superior to those of holders of Common Shares. Any debt financing that the Company may secure in the future could involve debt service obligations and restrictive covenants. If the Company is unable to obtain adequate financing or financing on terms satisfactory to it when required, the Company's ability to continue to support its business growth, scale its infrastructure, develop product enhancements, and to respond to business challenges could be significantly impaired, and its business, results of operations and financial condition may be significantly adversely affected.

The Company may not be able to research and develop a successful product.

The Company's growth and long-term success is dependent in part on its ability to successfully develop products and we will likely incur significant research and development expenditures to do so. The Company cannot be certain that any investment in research and development will yield technically feasible or commercially viable products. Furthermore, its ability to discover and develop products will depend on its ability to retain key personnel, identify high-quality therapeutic targets and unmet medical needs, successfully complete clinical trials on humans, obtain and maintain necessary intellectual property rights to the Company's products, and obtain and maintain necessary regulatory approvals for its products. The Company may not be successful in discovering and developing medical device products. Failure to introduce and advance new and current products could materially and adversely affect the Company's operations and financial condition.

Risk Factors Continued

If the Company is unable to protect its intellectual property rights adequately, competitors may be able to use its technologies, which could substantially diminish the value of the Company's products.

The Company's future success depends in part on its ability to obtain and maintain patent and other intellectual property protection for its technology. If the Company's patents and other intellectual property do not adequately protect its technology, competitors may be able to offer products similar to the Company's. Competitors may also be able to develop similar technology independently or design around any patents granted to the Company, and it may not be able to detect the unauthorized use of its proprietary technology or take appropriate steps to prevent such use. Any such activities by competitors that circumvent the Company's intellectual property protection could subvert its competitive advantage and have an adverse effect on its results of operations.

The Company may be sued by third parties for alleged infringement of their proprietary rights, which could adversely affect the Company's business, results of operations and financial condition. There is often litigation between competing companies relying on their respective technologies based on allegations of infringement or other violations of intellectual property rights. The Company's future success depends, in part, on not infringing the intellectual property rights of others. The Company may receive claims from third parties, including its competitors, alleging that its platform and its underlying technology infringe or violate such third party's intellectual property rights, and the Company may be found to be infringing upon such rights.

The Company may be unaware of the intellectual property rights of others that may cover some or all of its technology. Any such claims or litigation could cause the Company to incur significant expenses and, if successfully asserted against the Company, could require that the Company pay substantial damages or ongoing royalty payments, prevent the Company from offering some portion of its platform, or require that it comply with other unfavorable terms. Litigation is inherently expensive and uncertain, and any judgment or injunctive relief entered against the Company or any adverse settlement could negatively affect its business, results of operations and financial condition.

Risk Factors Continued

If the Company is not able to obtain, or if there are delays in obtaining, required regulatory approvals, the Company may not be able to fully realize the expected value of products, and long-term profitability of the products may be materially impaired.

The Company's products and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, record keeping, labeling, storage, approval, advertising, promotion, sale, and distribution, are subject to comprehensive regulation. Failure to obtain regulatory approval for a product will prevent the Company from commercializing it. The Company has not received regulatory approval to market any of its products in any jurisdiction. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory bodies to establish a product's safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the applicable regulatory authority.

The process of obtaining regulatory approvals is expensive, may take many years if additional clinical trials are required, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the products involved. Changes in regulatory approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory bodies have substantial discretion in the approval process and may refuse to accept any application or may decide that the Company's data is insufficient for approval and require additional preclinical, clinical, or other studies.

In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit, or prevent regulatory approval of a product. Any regulatory approval the Company ultimately obtains may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. If the Company experiences delays in obtaining approval or if it fails to obtain approval of its products, the commercial prospects for the Company's products may be harmed and its ability to generate revenues will be materially impaired.

Statutory Rights of Action – Canada

Statutory Rights of Action

Securities legislation in certain of the provinces of Canada may deem this Presentation to be an offering memorandum and accordingly provide purchasers with statutory rights of rescission or damages, or both, in the event this Presentation contains a misrepresentation. A "misrepresentation" is an untrue statement of a material fact or an omission to state a material fact that is required to be stated or that is necessary to make any statement not misleading or false in light of the circumstances in which it was made. These remedies must be commenced by the purchaser within the time limits prescribed and are subject to the defenses contained in the applicable securities legislation. Purchasers should refer to the applicable provisions of the securities legislation of their province for the particulars of these rights or consult with a legal advisor.

The rights of action described below are in addition to and without derogation from any other right or remedy available at law to the purchaser and are intended to correspond to the rights against an issuer of securities provided in the relevant securities legislation and are subject to the defenses contained therein.

Ontario

Ontario Securities Commission Rule 45-501 provides that when an offering memorandum is delivered to an investor to whom securities are distributed in reliance upon certain of the prospectus exemptions in the *Securities Act* (Ontario) or National Instrument 45-106 – *Prospectus Exemptions* ("NI 45-106"), respectively, the right of action referred to in Section 130.1 of the *Securities Act* (Ontario) ("Section 130.1") is applicable unless the prospective purchaser is: (a) a Canadian financial institution; (b) a Schedule III bank; (c) the Business Development Bank of Canada; or (d) a subsidiary of any person referred to in paragraphs (a) or (b), if the person owns all of the voting securities of the subsidiary, except the voting securities required by law to be owned by the directors of the subsidiary.

Statutory Rights of Action – Canada

Statutory Rights of Action – Ontario (continued)

Section 130.1 provides purchasers who purchase securities offered by an offering memorandum with a statutory right of action against the issuer of securities and any selling securityholder for rescission or damages in the event that the offering memorandum or any amendment to it contains a “misrepresentation”, without regard to whether the purchaser relied on the “misrepresentation”. “Misrepresentation” means an untrue statement of a material fact or an omission to state a material fact that is required to be stated or that is necessary to make any statement not misleading in light of the circumstances in which it was made.

In the event that this Presentation, together with any amendment, is delivered to a prospective purchaser of securities in connection with a trade made in reliance on certain of the prospectus exemptions in the *Securities Act* (Ontario) or NI 45-106, and this presentation contains a misrepresentation which was a misrepresentation at the time of purchase of the securities, the purchaser will have a statutory right of action against the Company for damages or, while still the owner of the securities, for rescission, in which case, if the purchaser elects to exercise the right of rescission, the purchaser will have no right of action for damages, provided that:

- (a) no action shall be commenced more than, in the case of an action for rescission, 180 days after the date of the transaction that gave rise to the cause of action; or in the case of any other action, the earlier of (i) 180 days after the plaintiff first had knowledge of the facts giving rise to the cause of action, or (ii) three years after the date of the transaction that gave rise to the cause of action;
- (b) the defendant will not be liable if it proves that the purchaser purchased the securities with knowledge of the misrepresentation;
- (c) the defendant will not be liable for all or any portion of the damages that it proves do not represent the depreciation in value of the securities as a result of the misrepresentation relied upon;
- (d) in no case will the amount recoverable exceed the price at which the securities were offered to the purchaser; and

Statutory Rights of Action – Canada

Statutory Rights of Action – Ontario (continued)

(e) the statutory right of action for rescission or damages is in addition to and does not derogate from any other rights or remedies the purchaser may have at law.

This summary is subject to the express provisions of the *Securities Act* (Ontario) and the regulations and rules made under it, and purchasers should refer to the complete text of those provisions.



A Better Path to Well

INVESTOR PRESENTATION | CONFIDENTIAL | February 2026